News Story: Patent applied for Iodine

Co. seeks patent for Iodine treatment
Written by Matthew L. Brown
Thursday, 26 July 2007


http://wbjournal.com/j/index.php?option=com_content&task=view&id=2127&Itemid=129



Symbollon Pharmaceuticals Inc. of Framingham has applied for a patent claiming its IoGen compound can fight cancer by preventing excess tissue growth in women's reproductive organs.

The application extends Symbollon's proprietary coverage of administering its active agent, molecular iodine, therapeutically to humans.

The new patent claims cover chronic administration of IoGen to treat excess cell growth in the breast, ovaries, and uterus, as well as its ability to control the level of estrogen receptors in women at risk for breast or ovarian cancer.

Symbollon is currently conducting a clinical trial designed to evaluate the effectiveness of IoGen for the treatment of moderate to severe cyclic pain and tenderness associated with fibrocystic breast disease. The results of the study should be available in the first quarter of 2008, the company said.